Advanced visualization software firm Imaging Biometrics has renewed its distribution agreement with GE HealthCare (GEHC).
Under the agreement, GEHC will now sell Imaging Biometrics’ IB Neuro and IB Delta T1 platforms directly to both existing and new customers. IB Neuro and IB Delta T1 maps are frequently used together to assist in diagnosing, planning, and monitoring treatment response for brain tumor patients, Imaging Biometrics said.
Delta T1 maps provide objective and rapid delineation of contrast-enhancing regions, while IB Neuro generates MR perfusion images that accurately measure relative cerebral blood volume (rCBV) using a contrast leakage correction algorithm. IB Neuro’s rCBV perfusion maps, derived from dynamic susceptibility contrast MRI, are used for tumor assessment and have demonstrated the ability to distinguish between true tumor regrowth and normal treatment effects, the company noted.
